Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

8.140 +0.030 (+0.37%)

Streaming Delayed Price Updated: 12:48 PM EST, Dec 19, 2025 Add to My Watchlist

Price and Volume

Volume	96,119
Open	8.130
Bid (Size)	8.030 (300)
Ask (Size)	8.200 (100)
Prev. Close	8.110
Today's Range	8.000 - 8.520
52wk Range	3.280 - 9.821
Shares Outstanding	41,957,197
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Which stocks are gapping on Monday? ↗

December 01, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Top stock movements in today's session. ↗

November 28, 2025

Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

Performance

YTD	+15.9%	+15.9%
1 Month	+112.5%	+112.5%
3 Month	+101.5%	+101.5%
6 Month	+39.2%	+39.2%
1 Year	+26.6%	+26.6%

More News

Which stocks are moving on Friday? ↗

November 28, 2025

Via Chartmill

What to Expect from Verrica Pharmaceuticals's Earnings ↗

August 11, 2025

Via Benzinga

Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway

November 24, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

November 14, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting

November 10, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 24, 2025

From Halper Sadeh LLC

Via Business Wire

Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union

October 20, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 07, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Top movers in Friday's pre-market session ↗

September 19, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 19, 2025

Via Benzinga

Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum

September 19, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Posts Profit in Fiscal Q2 ↗

August 12, 2025

Via The Motley Fool

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 06, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 17, 2025

Via Benzinga

Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025

July 09, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 01, 2025

Via Benzinga

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

July 01, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

May 28, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results

May 13, 2025

From Verrica Pharmaceuticals Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?

Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.

What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?

Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?

The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market

What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?

The current price of Verrica Pharmaceuticals Inc. - Common Stock is 8.140

When was Verrica Pharmaceuticals Inc. - Common Stock last traded?

The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 12/19/25 12:48 PM ET

What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?

The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 341.53M

How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?

Verrica Pharmaceuticals Inc. - Common Stock has 342M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.